Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Operating activities
Net loss	$ (308,020,000)	$ (25,751,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	5,942,000	14,549,000
Stock–based compensation expense	77,800,000	82,114,000
Net accretion of discounts on marketable securities	(28,952,000)	(31,709,000)
Non-cash adjustment to operating lease expense	(3,025,000)	(2,762,000)
Right-of-use asset amortization for finance lease	431,000	0
Non-cash gain from divestiture of small molecule programs	(14,537,000)	0
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(2,625,000)	1,910,000
Other non-current assets	(1,178,000)	0
Accounts payable	151,000	4,512,000
Accruals and other current liabilities	6,090,000	(11,665,000)
Related-party contract liability	0	(290,532,000)
Deferred research and development funding liability, less current portion	3,944,000	0
Net cash used in operating activities	(263,979,000)	(259,334,000)
Investing activities
Purchases of marketable securities	(1,056,263,000)	(1,399,982,000)
Maturities and sales of marketable securities	806,120,000	1,586,947,000
Purchases of property and equipment	(10,820,000)	(10,704,000)
Net cash (used in) provided by investing activities	(260,963,000)	176,261,000
Financing activities
Proceeds from issuance of common stock and pre-funded warrants, net of issuance costs of $480K	499,253,000	0
Proceeds from exercise of awards under equity incentive plans	13,234,000	13,115,000
Payments for finance lease right-of-use asset	(24,015,000)	0
Net cash provided by financing activities	488,472,000	13,115,000
Net decrease in cash, cash equivalents and restricted cash	(36,470,000)	(69,958,000)
Cash, cash equivalents and restricted cash at beginning of period	128,681,000	219,544,000
Cash, cash equivalents and restricted cash at end of period	92,211,000	149,586,000
Supplemental disclosures of cash flow information
Increase in right-of-use asset due to lessor assets	7,051,000	0
Non-cash recognition of new finance lease	5,689,000	0
Cash paid for finance lease interest	121,000	0
Cash paid during the period for income taxes	0	4,000
Equity consideration received in the divestiture of small molecule programs (Note 10)	15,000,000	0
Property and equipment purchases accrued but not yet paid	$ 263,000	$ 6,230,000